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Macrophages have important protective functions during infection with herpes simplex virus
type 1 (HSV-1). However, molecular mechanisms that restrict viral propagation and protect from
severe disease are unclear. Here we show that macrophages take up HSV-1 via endocytosis and
transport the virions into multivesicular bodies (MVBs). In MVBs, acid ceramidase (aCDase)
converts ceramide into sphingosine and increases the formation of sphingosine-rich intraluminal
vesicles (ILVs). Once HSV-1 particles reach MVBs, sphingosine-rich ILVs bind to HSV-1 parti-
cles, which restricts fusion with the limiting endosomal membrane and prevents cellular
infection. Lack of aCDase in macrophage cultures or in Asah1−/− mice results in replication of
HSV-1 and Asah1−/− mice die soon after systemic or intravaginal inoculation. The treatment of
macrophages with sphingosine enhancing compounds blocks HSV-1 propagation, suggesting a
therapeutic potential of this pathway. In conclusion, aCDase loads ILVs with sphingosine, which
prevents HSV-1 capsids from penetrating into the cytosol.
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Macrophages are one of the most important componentsof the innate immune system. With their strong pha-gocytic capacity they engulf pathogens early after their
invasion and inactivate them by proteolysis1. Especially during
virus infection, macrophages are the key effector cells of innate
immunity. Mice lacking macrophages are highly susceptible for
instance to mouse hepatitis virus, lymphocytic choriomeningitis
virus and vesicular stomatitis virus and show overwhelming viral
propagation2–4. The contribution of macrophages to control of
systemic infection was linked to their capacity to internalize
infectious particles and limit their propagation in a type I inter-
feron (IFN-I) dependent manner, which leads to upregulation of
the antiviral genes Mx, OAS, RNase L and Protein kinase R4.
While these antiviral mechanisms require hours after infection to
become active, macrophages also exhibit robust antiviral sup-
pression already minutes after virus inoculation4–6, suggesting the
presence of preexisting IFN-I-independent antiviral mechanisms.
However, these mechanisms are poorly defined.
Herpes simplex virus type 1 (HSV-1) is an enveloped DNA
virus, which can replicate in several different cell types7. After
binding to a target cell, HSV-1 either fuses directly with the
plasma membrane or is taken up into endosomes of the cell8,9.
Within these endosomes fusion of the outer limiting membrane
with HSV-1 membrane leads to infection of the cells in a pH
dependent manner10. Upon penetration, the HSV-1 capsid traf-
fics on microtubules to the nucleus11,12, uncoats its DNA genome
at the nuclear pore complex13,14, and delivers the genome to the
nucleus for replication and assembly of capsids15,16. Newly
formed capsids bud through the nuclear envelope17 and exit the
infected cell through the secretory pathway or by cell lysis18,19. In
an HSV-1 infection model, macrophages play an essential role20.
This is linked to the high IFN-I sensitivity of HSV-1, which limits
the replication of HSV-1 DNA and the production of newly
formed capsids21,22. Interestingly even in the absence of IFN-I
replication of HSV-1 is restricted in macrophages, a phenome-
non that could be explained by limited uptake of HSV-1 into
macrophages or an aggravated or limited infection of the mac-
rophage after HSV-1 has entered the endosome. Whether indeed
macrophage-specific mechanisms regulate HSV-1 infection
remains unknown.
Mulitvesicular bodies (MVBs) are complex membrane rich
organelles of the cytoplasm, which contain high numbers of
vesicles. These so called intraluminal vesicles (ILVs) are formed
by invagination and budding from the outer limiting membranes
(OLMs) into the MVB lumen and play a crucial role in sorting,
degrading, and recycling of proteins23. Sphingolipids are enriched
in MVBs and are involved in the MVB biogenesis and the reg-
ulation of their functions24. Thereby sphingolipids modulate
diverse cellular processes, including proliferation, differentiation,
apoptosis, signal transduction, and membrane trafficking25–27.
Modulation of biophysical membrane properties such as fluidity,
polarity, vesicle formation, and deformation is one major factor
of the regulatory capacity of sphingolipids28. A key enzyme in
sphingolipid metabolism in MVBs is the acid ceramidase
(aCDase)29–31. It catalyzes the degradation of ceramide into
sphingosine and free fatty acid, which modulates the shape and
the charge of membranes. Whether this process can modulate
HSV-1 entry remains unknown.
Here we analyze whether the aCDase dependent modulation of
membrane properties can affect HSV-1 entry after uptake into
macrophages. In a model of HSV-1 infection in bone marrow
derived murine macrophages (BMDMs) we found that strong
activity of aCDase blocks the fusion of the HSV-1 membrane with
the outer limiting membrane of MVBs. Antiviral activity of
aCDase is independent of IFN-I, but aCDase expression is
dependent on IRF8 during macrophage development. In vivo,
expression of aCDase in macrophages limits early steps of HSV-1
propagation and protects mice from severe outcome of infection.
Results
Macrophages control HSV-1 infection. To prove the importance
of macrophages during herpes simplex virus type 1 (HSV-1)
control in vivo, we infected C57BL/6 mice intravenously with
HSV-1 and then analyzed the distribution of virus in the liver by
histology. Naïve mice and HSV-1 infected macrophage-depleted
mice served as controls. 1 h after infection most of the virus
inoculum co-localized with F4/80+ macrophages within the liver
(Fig. 1a), suggesting that macrophages are equipped to take up
HSV-1 quickly after systemic administration. Naïve mice did not
show HSV-1 staining (Fig. 1a) and macrophage-depleted mice
showed no F4/80+ cells in spleen and liver and no co-localization
(Supplementary Fig. 1)4. To obtain insights on the functional role
of macrophages we treated C57BL/6 mice with clodronate-
liposomes to deplete macrophages. Control mice were treated
with control-liposomes and all mice were infected with HSV-1. In
the presence of macrophages, HSV-1 replication was nearly
undetectable 24 h after infection (Fig. 1b, c). In strong contrast,
HSV-1 showed overwhelming replication in the absence of
macrophages (Fig. 1b, c). Enhanced replication of HSV-1 corre-
lated with production of infectious HSV-1 in liver and spleen of
macrophage deficient mice (Fig. 1d). In line with overwhelming
virus propagation, macrophage deficient mice developed liver cell
damage and died quickly after infection (Fig. 1e, f). To analyze the
importance of macrophages during a natural infection route, we
infected mice intravaginal with HSV-1 and analyzed local repli-
cation of HSV-1 and outcome of the infection. Local HSV-1
replication and production of infectious particles was comparable
between control and macrophage-depleted mice (Fig. 1g, h).
However, macrophage-depleted mice died after intravaginal
infection while control mice were protected (Fig. 1i). This sug-
gests that macrophages in the vagina do not limit early local
HSV-1 replication, while, macrophages are critical for the sys-
temic control of HSV-1. In conclusion, we found that macro-
phages do play an essential role to protect from systemic HSV-1
propagation.
aCDase in multivesicular bodies traps HSV-1. As elucidated in
Fig. 1, macrophages are of high importance to limit HSV-1
propagation during systemic infection. Following this, we aimed
to investigate antiviral mechanisms that are specific to macro-
phages. To get insights into the macrophage-specific antiviral
mechanism we generated bone marrow derived macrophages
(BMDMs) and compared their antiviral activity to isolated
alveolar fibroblasts. HSV-1 propagated strongly in fibroblasts and
infectious HSV-1 was released into the supernatant (Fig. 2a, b). In
contrast to fibroblasts, HSV-1 showed limited propagation in
macrophages and infectious particles were hardly measurable in
the supernatants (Fig. 2a, b). Even higher infection doses up to
MOI 1 did not result in productive infection in cultured mac-
rophages (Fig. 2b). Treatment with interferon-α4 (IFN-α4)
reduced the infectious particles (Fig. 2b), however the striking
difference in virus production between fibroblasts and macro-
phages remained. These results suggest that administration of
type I interferon (IFN-I) cannot induce the strong antiviral
capacities of macrophages in fibroblasts. While there are multiple
differences between macrophages and fibroblasts, we hypothe-
sized that macrophages have specific antiviral protection
mechanisms independent of the presence of IFN-I.
To explore potential antiviral mechanisms we performed
microarray analysis to compare cellular pathways between
macrophages and fibroblasts. The strongest difference between
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fibroblasts and macrophages was the high expression of
endosomal, lysosomal and vesicular transport pathways in
macrophages (Fig. 2c). From these data, we considered it likely
that in macrophages the vesicular trafficking of HSV-1 might be
extraordinary, and therefore restricts a productive infection. To
directly visualize HSV-1 entry in macrophages and fibroblasts, we
performed electron microscopy of macrophages and fibroblasts,
which were infected with HSV-1 (MOI 250) for 30 min. We chose
30 min, as this is the time that HSV-1 requires to enter cells and
first incoming capsids to reach the nuclear envelope of fibroblasts
or epithelial cells11,32–34. Indeed, 30 min after infection we
detected first viral capsids at the nuclear envelope of fibroblasts,
but no newly produced viral capsids (Supplementary Fig. 2).
Therefore we concluded that 30 min is an ideal time point to
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analyze the early internalization and intracellular distribution of
HSV-1 within the cell. As expected, we found in macrophage and
fibroblast cell cultures HSV-1 virions close to the plasma
membrane (Fig. 2d). In macrophages, about 30% of all particles
were found in endosomes and significantly more particles,
about 50% of all particles, were found in multivesicular bodies
(Fig. 2d, e). We could hardly detect viral capsids in the cytosol of
macrophages (Fig. 2d, e). In fibroblasts, HSV-1 was detectable in
vesicular compartments like early endosomes, late endosomes,
MVBs and/or lysosomes (Fig. 2d). In addition electron micro-
scopy revealed cytosolic capsids after 30 min of infection (Fig. 2d),
indicating fusion of the viral envelopes with host membrane and
11′
6′
1′
2′
9′
10′
13′ 
8′
14′
7′
4′
12′
12
9
11
28
45
13
52
17
22
49
51
35
53
31
19
15
16
1
43
44
29
47
55
32
39
42
41
54
18
40
4
33
3
46
34
24
20
48
23
10
25
38
27
21
36
26
50
37
30
2
5
6
8
Clathrin-coated
membranes
Endocytosis
Lysosome
Late endosome
Early
endosome
Mitochondria
Cell division
Chromosomal
region Proton
transport
complex
Microtubule
Platelet alpha
granule
6
##
##
##
## ##
#
## ##
##
H
S
V
-1
 (
lo
g 1
0 
T
C
ID
50
/m
l)
MacrophagesFibroblasts
a b
e
f
g
h
c
d Macrophages
Extracellular Extracellular
Extracellular
Endosome
Endosome
MVB
MVB
Cytosol
Extracellular
Endosome
MVB
Cytosol
Cytosol
Endosome
MVB
Cytosol
Fibroblasts
Macrophages
Macrophages
Fibroblasts
Fibroblasts, IFN-α
Macrophages, IFN-α
H
S
V
-1
, H
oe
ch
st 5
4
3
2
1
<1
MOI 0.01
6
H
S
V
-1
 (
lo
g 1
0 
T
C
ID
50
/m
l)
5
4
3
2
1
<1
MOI 1
3′
5′
ER/Golgi
Projection
membranes
Anchoring
junction
Gap junction,
connexion
Extracellular
matrix
7
Ungrouped
14
# genes in pathway
5200S
iz
e
NES
Fibroblast Macrophage
Node
Edge
Gene overlap
0 2–2
S
iz
e
Overlap size
C
ol
or
80
60
40
20
0
H
S
V
-1
(%
 o
f t
ot
al
 H
S
V
-1
 p
ar
tic
le
s)
Ex
tra
ce
llu
lar
En
do
so
m
es
M
VB
Cy
to
so
l
E
xp
re
ss
io
n 
m
ac
ro
ph
ag
es
Expression fibroblasts
Control IFN-α treated
15
10
5
0
4
A
sa
h1
 (
re
la
tiv
e 
ex
pr
es
si
on
)
3
2
1
0
75 kDa
aCDase
GAPDH
50 kDa
37 kDa
25 kDa
0 1 2 3
E
xp
re
ss
io
n 
m
ac
ro
ph
ag
es
Expression fibroblasts
15
10
PIcl2
PIcg2
PIcb2PIcb2
PIcg2
PIcl2
Sphk2
Asah1
Smpd3 Asah1
5
0
0 1 2 3
Macrophages
Fibroblasts
M
ac
ro
ph
ag
es
Fi
br
ob
las
ts
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15072-8
4 NATURE COMMUNICATIONS |         (2020) 11:1338 | https://doi.org/10.1038/s41467-020-15072-8 | www.nature.com/naturecommunications
successful capsid delivery into the cytosol. From these results we
concluded that after HSV-1 is internalized by macrophages, it
passes early and late endosomes and accumulates in MVBs but
cannot deliver its capsid through the outer limiting membrane to
the cytosol. This phenomenon might be responsible for limited
productive infection in macrophages.
To determine why HSV-1 fails to release its capsid through the
outer limiting MVB membrane in macrophages, we analyzed our
microarray data for differences in membrane-modulating proteins.
Strikingly we found overexpression of phospholipase C subtypes,
neutral sphingomyelinase (Nsm, Smpd3) and acid ceramidase
(aCDase, Asah1) in macrophages (Fig. 2f) in comparison to
fibroblasts. Differential expression of these proteins was indepen-
dent of IFN-I (Fig. 2f). Using real-time polymerase chain reaction
(RT-PCR) and Western blot analysis we confirmed the high
expression of Asah1 mRNA and cleaved, i.e., activated, aCDase
protein in macrophages compared to fibroblasts (Fig. 2g, h,
Supplementary Fig. 7). From these experiments we concluded that
macrophages accumulate HSV-1 in MVBs without being produc-
tively infected. This strong antiviral activity of macrophages
correlated with aCDase expression.
aCDase limits HSV-1 infection and prevents disease. Since we
identified that aCDase is a membrane modulating molecule that
is highly expressed in macrophages, we next analyzed the antiviral
activity of aCDase. WT macrophages showed limited propagation
of HSV-1 (Fig. 3a, b). In strong contrast macrophages that lack
aCDase (Asah1−/−) showed strong propagation of HSV-1
(Fig. 3a, b). Next we tested the role of aCDase in vivo. We
infected WT and Asah1−/− mice with HSV-1. In Asah1−/− mice,
HSV-1 showed overwhelming propagation after 12 h to 3 days
(Fig. 3c, d) and infectious particles were produced in spleen and
liver of Asah1−/−, but not control mice (Fig. 3e). Next we aimed
to determine the importance of Asah1 in relation to the known
anti-HSV-1 effectors type I interferon (IFN-I)35 and SAMHD136.
Therefore we infected mice, which show limited production of
IFN-I (MyD88−/− x Trif−/− x Cardif−/− mice), limited response
to IFN-I (Ifnar−/− mice) and mice, which lack SAMHD1
(Samhd1−/− mice), with HSV-1. Similarly to Asah1−/− mice,
Ifnar−/− mice and MyD88−/− x Trif−/− x Cardif−/− mice
showed highly elevated HSV-1 DNA in lymph node, spleen and
liver, when compared to control mice (Supplementary Fig. 3).
In Samhd1−/− mice HSV-1 DNA levels were elevated in the
liver (Supplementary Fig. 3). In Ifnar−/− mice and MyD88−/− x
Trif−/− x Cardif−/− mice, but not in Samhd1−/− mice, we
detected infectious HSV-1 particles in liver and spleen after
HSV-1 infection, which was comparable to HSV-1 production in
Asah1−/− mice (Fig. 3f). From these data we considered aCDase
to be an important antiviral effector mechanism.
To determine the macrophage-specific role of aCDase we
generated bone marrow chimeras, in which Asah1−/− bone
marrow was transplanted into macrophage-depleted WT mice. In
these mice macrophages repopulate from Asah1−/− bone
marrow. Chimeric mice with aCDase-deficient macrophages
showed enhanced HSV-1 copies when compared to control mice
(Fig. 3g), suggesting that indeed aCDase in macrophages
contributed to control of HSV-1. To determine the overall
importance of aCDase during systemic and local infection
we infected Tamoxifen treated Cre-ER Asah1fl/fl (inducible
aCDase-deficient mice) with HSV-1. aCDase deficient Cre-ER
Asah1fl/fl mice died quickly after systemic and local intravaginal
infection (Fig. 3h, i). Therefore we conclude that aCDase is an
important effector mechanism against HSV-1, which acts in
macrophages.
Sphingosine protects against HSV-1 infection. After analyzing
aCDase deficiency, we investigated effects of increasing sphingoli-
pid content during HSV-1 infection. From literature it is known
that aCDase is usually active in lysosomes and MVBs29–31,37.
To test whether aCDase directly interacts with HSV-1, we infected
macrophages with HSV-1 and stained for aCDase and HSV-1 after
30min. HSV-1 and aCDase were in close approximation, however
we did not see a direct co-localization of aCDase with HSV-1
(Fig. 4a). This suggests that aCDase is not directly modulating
HSV-1, but might modulate cellular components such as MVBs,
which affect HSV-1 infection. Functionally, aCDase converts cer-
amide into sphingosine (Fig. 4b) and we considered that
enhancement of sphingosine in MVBs was the reason for viral
protection in WT macrophages against HSV-1. Indeed, addition of
CDase 30min before infection limits HSV-1 propagation, which
suggests that the enzymatic function is most relevant for the anti-
viral activity (Fig. 4c, d).To reveal the role of sphingosine in HSV-1
infection, we treated macrophages with sphingosine (Sph), sphin-
gomyelinase (SMase), and sphingosine kinase inhibitor (SKI-II),
which are all involved in sphingolipid pathway and could enhance
sphingosine levels38. Sphingosine treatment, which strongly ele-
vated total sphingosine levels of primary macrophages and the
Raw264.7 macrophage cell line (Supplementary Fig. 4), suppressed
propagation of HSV-1 (Fig. 4c–e). Treatment with ceramidase,
sphingomyelinase, and sphingosine kinase inhibitor resulted in
smaller increases of cellular sphingosine levels and a corresponding
suppression of HSV-1 propagation (Fig. 4c–e, Supplementary
Fig. 4). From these data we concluded that enhanced amount of
sphingosine was most likely the reason for antiviral activity in the
presence of aCDase. To determine whether sphingosine acted cell
type specific, we tested the antiviral activity of sphingosine in dif-
ferent cell types including human monocytes (THP-1), human
cervix carcinoma cells (HeLa) and monkey kidney cells (Vero). To
note, HSV-1 infects Vero cells via fusion at the plasma membrane
while HeLa cells are infected after HSV-1 is endocytosed10,11,39,40.
We found that sphingosine and/or SKI-II acted antiviral in
undifferentiated THP-1 and HeLa cells (Fig. 4f, g). However we
Fig. 2 aCDase in multivesicular bodies traps HSV-1. a, b Immunofluorescence (a) and tissue culture infection dose 50 (TCID50) from supernatants (b) of
fibroblasts or bone marrow derived macrophages (BMDMs) that were infected with herpes simplex virus type 1 (HSV-1) at a multiplicity of infection (MOI)
of 10 and stained after 6 h (a, n = 4; scale bar 50 µm) or MOI 0.01 or MOI 1 and supernatant was collected after 24 h (b, n= 8; one-way ANOVA [Tukey’s
multiple comparison]). c Gene set enrichment analysis (GSEA) of microarrays showing gene sets enriched in macrophages (red) vs. gene sets enriched in
fibroblasts (blue). See Supplementary Table 1a, b for gene sets, ranking and grouping. NES: normalized enrichment score. ER: endoplasmic reticulum.
d, e Representative electron microscopic images (d) and quantification (e) of wild-type (WT) BMDMs and/or fibroblasts infected with HSV-1 (MOI 250)
analyzed after 30min (BMDMs: n= 77 images from three independent experiments, scale bar 5 µm; Fibroblasts: n= 106 images from three independent
experiments, scale bar 5 µm, one-way ANOVA [Tukey’s multiple comparison]). Overview of one macrophage and one fibroblast is shown. Details show
specific compartments containing HSV-1. MVB: multivesicular bodies. f: Expression of membrane-modulating proteins analyzed from microarrays of
fibroblasts and macrophages with or without 50 U/ml interferon-α4 (IFN-α4) treatment. g Real-time polymerase chain reaction (RT-PCR) for Asah1mRNA
expression of fibroblasts and macrophages from WT mice (n= 6, two-tailed student’s t-test). h Western Blot for aCDase protein expression of fibroblasts
and macrophages from WT mice (1 of 2 is shown). All data are shown as mean ± SEM. *p≤ 0.05, **p≤ 0.01, #p≤ 0.001, ##p≤ 0.0001.
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found limited antiviral activity of sphingosine in Vero cells
(Fig. 4h), suggesting that the cell type and/or the route of infection
might limit the antiviral activity of sphingosine. Taken together we
concluded, that sphingosine, which is produced by aCDase in
MVBs is antivirally active in macrophages.
Sphingosine-rich intraluminal vesicles trap HSV-1. Next we
aimed to determine the mechanism, how aCDase and
sphingosine limit HSV-1 infection in macrophages. To this end,
we incubated cells for 30 min with an HSV-1 carrying a fluor-
escently labeled tegument (HSV-1-VP16-GFP), and stained with
an antibody for viral capsids (VP541), which recognizes the
uncoated capsid after virus membrane fusion. In this experi-
mental setup capsid is only visible after dissociation of the
tegument11. We mainly observed HSV-1-VP16-GFP puncta, in
WT macrophages (Fig. 5a, b), indicating that the HSV-1 capsids
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were not released from the envelope. In strong contrast, in
aCDase lacking (Asah1−/−) macrophages we detected almost
exclusively exposed capsids without tegument (Fig. 5a, b), sug-
gesting that the capsids were released from the envelope and the
tegument due to virus infection. To get more insights into the
reason for limited infection in WT macrophages, we performed
electron microscopy experiments in WT and Asah1−/− macro-
phages. WT and Asah1−/− macrophages showed similar amounts
of HSV-1 particles attached to the plasma membrane (Fig. 5c, d).
In line, similar amounts of HSV-1 particles were detected in WT
and Asah1−/− macrophages in endosomes and MVB (Fig. 5c, d).
In WT macrophages HSV-1 particles were located in close
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proximity to the ILVs, and in some cases appeared to fuse with
ILVs (Fig. 5c, d). This correlated with trapping of HSV-1 in ILVs
(Fig. 5c, d). In contrast, in Asah1−/− macrophages, the HSV-1
envelopes were more frequently associated with the outer limiting
membranes (OLMs) of the MVBs (Fig. 5c, d), so that membrane
fusion here led to a productive release of capsids into the cytosol
and infection of the cell. Therefore, we concluded that aCDase-
derived sphingosine mediates binding of HSV-1 envelope to ILVs
membrane, which results in trapping of the virus.
To prove that indeed sphingosine on ILVs interacted with
HSV-1 we loaded WT macrophages with ω-azido-sphingosine,
which can be visualized by a click reaction42. 3 h after sphingosine
loading, we infected cells with HSV-1 and co-stained cells with
the ILV marker CD9. Indeed, sphingosine accumulated in ILVs
(Fig. 5e). As expected HSV-1 co-stained with these sphingosine-
rich ILVs (Fig. 5e). To determine that indeed sphingosine is
responsible for interaction between HSV-1 and ILVs, we
generated liposomes and loaded them either with ceramide or
sphingosine. Liposomes were then incubated with HSV-1 and
binding of virions was analyzed after 10 min by flow cytometry.
Control and ceramide-liposomes did not bind HSV-1 (Fig. 5f, g).
In contrast, sphingosine-liposomes bound HSV-1 (Fig. 5f, g).
Concluding, we found that the antiviral effects of aCDase are
mediated via fusion of viral envelop to sphingosine containing
ILVs of MVBs.
IRF8, but not IFN-I signaling, induces aCDase expression. Our
data show that the Asah1 gene encoding aCDase is a crucial factor
involved in antiviral protection against HSV-1. Next, we aimed to
define, how aCDase expression is induced. We aimed to analyze
whether Asah1 is also induced by IFN-I. The results show that
Asah1 expression was hardly influenced by IFN-I, nor did Asah1
influence the induction of IFN-I or interferon induced genes
(Fig. 6a, b). Therefore we concluded that Asah1 is not specifically
upregulated during infection, but shows already basal activity in
macrophages before infection. To get insights how Asah1
expression is upregulated in macrophages we considered that
interferon regulatory factor 8 (IRF8) might play a role in this
process. IRF8 is a factor, which induces natural resistance in
macrophages during their development43,44. Furthermore, it was
shown that IRF8 regulates the expression of aCDase during the
induction of apoptosis in cancer cells45. RT-PCR analysis of
myeloid pre-cursor cells in the bone marrow revealed IRF8-
dependent upregulation of Asah1 (Supplementary Fig. 5). To
determine the role of IRF8 in regulating Asah1 in mature mac-
rophages, we analyzed Asah1 expression in the spleen, an
organ showing high numbers of macrophages. RT-PCR and
Western blot analysis revealed limited levels of Asah1 mRNA and
aCDase precursor protein in spleens of Irf8−/− mice when
compared to WT spleens (Fig. 6c, d, Supplementary Fig. 8). In
line, Irf8−/− mice showed elevated levels of HSV-1 DNA as well
as increased production of viral particles after infection with
HSV-1 (Fig. 6e, f). It has previously been reported, that IRF8
expression in human blood monocytes decreases with age, which
correlates with decreased expression of interferon stimulated
genes and might be a reason for impaired antiviral resistance to
influenza A virus (IAV)46. Whether this reduced IRF8 expression
influences also aCDase dependent virus control remains to be
studied. We concluded that Asah1 is not induced during infection
or by IFN-I, however IRF8 regulates Asah1 expression during
development of macrophages.
Discussion
Macrophages are one of the most important effector cells of the
innate immune system5,47. During infection with viruses such as
vesicular stomatitis virus (VSV), lymphocytic choriomeningitis
virus (LCMV), adenovirus or mouse hepatitis virus, macrophages
play a major protective role in limiting infection and preventing
severe disease2–4,48–50. In particular, tissue resident macrophages
such as Kupffer cells in the liver clear a range of systemic virus
infections4,48. Molecular mechanisms explaining this strong
antiviral activity are presently unknown. Here we found that
macrophages are essential for the control of HSV-1. With our
in vitro data, we linked the strong antiviral activity of macro-
phages to the expression of aCDase. aCDase produced
sphingosine-rich ILVs in MVBs. Once HSV-1 is taken up into
MVBs, sphingosine-rich ILVs bind to HSV-1 particles and
thereby trap them in MVBs and prevent infection of the cell.
Expression of aCDase was not regulated by IFN-I, but was
induced in macrophages in response to IRF8 signaling. While we
focused in our manuscript on the role of aCDase in macrophages,
our in vivo data suggest that aCDase exerts antiviral activity
probably also in other myeloid or even none-myeloid cell types.
It remains to be explored whether the restriction mechanism of
sphingosine-rich ILVs is specific for HSV-1 or whether also other
viruses are sensitive to sphingosine-rich ILVs. Interestingly, VSV,
the flaviviruses Japanese encephalitis virus (JEV) and yellow fever
virus (YFV) fuse with ILVs in MVBs51,52. Le Blanc et al.51 and
Nour et al.52 considered the release of viral capsids into ILVs a
relevant step in virus life cycle, and suggested that back-fusion of
ILVs, harboring capsids, with the OLMs of MVBs leads to pro-
ductive infection. Our data show that although back-fusion might
occur in macrophages, fusion of viral membrane with ILV
membrane is rather a cellular mechanism to limit infection of the
cell. Further experiments are required to determine whether other
enveloped viruses and non-enveloped viruses are also restricted
by sphingosine in MVBs.
Viruses frequently have an acidic isoelectric point at low pH53,
implying that these viruses are negatively charged at physiological
pH. The isoelectric point of HSV-1 is around 4.954. In contrast,
sphingosine is net positively charged at neutral or acidic pH, as
occurring in MVBs. We suggest that sphingosine gives ILVs a
positive charge, which facilitates the interaction with negatively
charged HSV-1. Indeed it was shown that sphingosine containing
vesicles interact with negatively charged membranes at the
plasma membrane or in late endosomes and accelerates fusion of
Fig. 5 Sphingosine-rich intraluminal vesicles trap HSV-1. a, b Representative images (a) and quantification (b) of immunofluorescence from wild-type
(WT) and Asah1−/− bone marrow derived macrophages (BMDMs) incubated with HSV-1-VP16-GFP (multiplicity of infection [MOI] 30) for 30min. Intact
viral particles are visible through GFP-tagged tegument protein VP16 (green). Exposed capsids were stained with anti-VP5 (red, n= 17 images, one of two
experiments is shown, scale bar 10 µm). c, d Representative electron microscopy images (c) and quantification (d) of WT and Asah1−/− BMDMs infected
with HSV-1 (MOI 250) analyzed after 30min (n= 68 WT images and n= 63 Asah1−/− images from three independent experiments; upper scale bar
400 nm, lower scale bar 200 nm, Mann-Whitney test). e Immunofluorescence of WT BMDMs, which were loaded with clickable ω-azido-sphingosine for
3 h, infected with HSV-1 (MOI 10) for 30min and then stained for sphingosine, the intraluminal vesicle (ILV) marker CD9, HSV-1 anti-capsid and Hoechst
(blue, n= 5, scale bar 20 µm). f, g Representative dot plots (f) and quantification (g) of control liposomes, ceramide-loaded liposomes and sphingosine-
loaded liposomes that were incubated with fluorescently labeled HSV-1 for 10min and then analyzed for HSV-1 binding in flow cytometry (n= 6, 2-way
ANOVA [Tukey’s multiple comparison]). All data are shown as mean ± SEM. *p≤ 0.05, **p≤ 0.01, #p≤ 0.001, ##p≤ 0.0001.
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Fig. 6 IRF8, but not IFN-I signaling, induces aCDase expression. a Real-time polymerase chain reaction (RT-PCR) of wild-type (WT) and Asah1−/− bone
marrow derived macrophages (BMDMs) that were left untreated, infected with herpes simplex virus type 1 (HSV-1) at a multiplicity of infection (MOI) of 1
for 24 h or infected and treated with 100 units interferon-α4 (IFN-α4; n= 10, one-way ANOVA [Dunnett’s multiple comparison]). b RT-PCR of WT and
Asah1−/− BMDMs that were left untreated or infected with HSV-1 at an MOI of 1 for 24 h (n= 10, two-tailed student’s t-test). c, d RT-PCR for Asah1 (c, n=
5, two-tailed student’s t-test) and Western blot for aCDase (d, n= 3) of spleen tissues fromWT and interferon regulatory factor 8 deficient (Irf8−/−) mice
that were left untreated. e, f RT-PCR (e) of lymph nodes (LN), spleens and livers and tissue culture infection dose 50 (TCID50, f) of spleens and livers from
WT and Irf8−/− mice that were infected with 2 × 106 TCID50 HSV-1 and analyzed on day 3 (n= 5-6, two-tailed student’s t-test). All data are shown as
mean ± SEM. *p≤ 0.05, **p≤ 0.01, #p≤ 0.001, ##p≤ 0.0001.
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these membranes55,56. More biophysical work is required to
better understand the interaction of HSV-1 with sphingosine.
We compared the in vivo phenotype of Asah1−/− mice during
HSV-1 infection to several other mouse strains, which show
limited production of IFN-I (MyD88−/− x Trif−/− x Cardif−/−
mice), limited response to IFN-I (Ifnar−/− mice) or lack
SAMHD1 (Samhd1−/− mice). SAMHD1 was previously reported
to be of importance for HSV-1 control in myeloid cells36,57 and
anti-viral effects can be evaded by some herpesviruses58. Viral
replication in Asah1−/− was comparable to MyD88−/− x Trif−/−
x Cardif−/− mice and Ifnar−/− mice and even enhanced to that in
Samhd1−/− mice. These findings indicate that Asah1 is an
important and major innate effector mechanism. We observed
increased HSV-1 DNA in livers of Samhd1−/− mice. This is in
line with other groups which determined an important role of
SAMHD1 on HSV-1 control in vitro36,57,58. How this lack
of HSV-1 control influences disease onset after HSV-1 infection
needs to be determined in the future. While SAMHD1 and IFN
signaling counteract mainly viral replication and production of
infectious particles, we think that aCDase protects macrophages
from infection with HSV-1 immediately after the virus is
taken up.
Our electron microscopy studies indicate that HSV-1 fuses
with ILVs. We consider that trapped viral particles are unable to
leave MVBs and are targeted to lysosomes for degradation. This
pathway of degradation might also facilitate antigen-presentation
and immune activation, as high numbers of tetraspanins and
MHC-II molecules are contained within ILVs23,59. More studies
are required to identify the relationship of aCDase, sphingosine
and antigen-presentation on MHC-II. In our study we focused
mainly on the role of sphingosine and aCDase in macrophages. In
addition, aCDase is expressed in several other tissues, especially in
lung, colon and stomach as well as spleen60 (Supplementary
Fig. 6). Cells in these organs are involved in building a barrier,
which protects against invading viruses. We consider it likely that
in addition to macrophages, potentially also other cell types
express aCDase in MVBs and are thereby protected against
invading viruses.
From our data we suggest enhanced virus infections in patients
with Farber disease, which are deficient in activity of aCDase61.
While such associations were not determined yet, patients with
Farber disease have a limited life span and die early after birth61.
Akin to other innate or adaptive deficiencies, a limited lifespan of
the patients may obscure a link between innate or adaptive
deficiencies to infectious agents62. Whether other mutations,
which affect the activity of aCDase, are widespread in the
population and whether such mutations influence the suscept-
ibility to viral infections will be subject to future studies.
In conclusion, we found that macrophages are essential to
survive an infection with HSV-1. Mechanistically, macrophages
took up HSV-1 and accumulated it in MVBs. aCDase in mac-
rophages enriched ILVs with sphingosine. Once HSV-1 entered
MVBs sphingosine-rich ILVs trapped HSV-1 and prevented
productive infection of the cells.
Methods
Mice. For acid ceramidase 1 (Asah1) deficient heterozygous mice, the exon-intron
organization of the gene was established on the basis of the Asah1 cDNA sequence.
A targeting vector was constructed, including Asah1 genomic sequences on the
C57BL/6 genetic background, a long homology region of 5.8 kb and a short
homology region of 1.7 kb. It also included two loxP sites flanking Asah1 exon 1, a
neomycin gene flanked by flipase recognition target sites for positive selection of
homologous recombination, and a diphtheria toxin, a negative-selection marker to
detect insertions and nonhomologous recombinant embryonic stem cell clones.
This targeting vector was inserted into C57BL/6 embryonic stem cells by homo-
logous recombination. Offspring were crossed with CreER mice (Gt[ROSA]
26Sortm9[cre/ESR1]Arte; Taconic Artemis Pharmaceuticals [Köln, Germany]). In
some experiments we used mice in which acid ceramidase deficiency could be
induced (Cre × Asah1fl/fl). CreER x Asah1fl/fl offspring express a Cre recombinase
under the tamoxifen promoter and the Asah1 gene with two LoxP sites flanking
exon 1. Administering tamoxifen thus led to the expression of Cre recombinase
and loss of function mutation by deletion of exon 1 in the Asah1 gene. In this
model, knock out of Asah1 occurs right before infection. Potential developmental
defects due to long term knock out of Asah1 are excluded in this model.
Asah1fl/fl x EIIa-Cre mice carry a Cre transgene under the control of the
adenovirus EIIa promoter that targets expression of Cre recombinase to the
early mouse embryo, and are used for germ line deletion of Asah1 gene, referred to
as Asah1−/− mice. Asah1−/− mice were on C57BL/6J background. Sibling
animals with the genotype Asah1+/+ were used as control animals. We bred
Irf8−/−, Ifnar−/−, MyD88−/− x Trif−/− x Cardif−/− and Samhd1−/− mice on
C57BL/6J background. Samhd1−/− mice were originally developed by Prof. Jan
Rehwinkel (MRC Human Immunology Unit, MRC Weatherall Institute of
Molecular Medicine, University of Oxford, Oxford, England)63.
All animals were housed in single ventilated cages. Animal experiments were
authorized by the Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV)
Nordrhein-Westfalen and in accordance with the German law for animal
protection and/or according to institutional guidelines at the Ontario Cancer
Institute of the University Health Network.
Cell lines, bone marrow macrophages. Raw264.7 cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA, #: ATCC: TIB-
71). THP-1 cells were purchased from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany, #: DSMZ: ACC 16). Vero cells
were provided by the Ontario Cancer Institute (Toronto, ON, Canada). HeLa cells
were provided in house (University Clinic Essen, Essen, Germany). For the gen-
eration of macrophages, bone marrow was isolated from mice and cultured for
9 days with macrophage colony-stimulating factor (M-CSF). Cells were plated on
new cell culture plates and the experiment was started the next day. For generation
of primary fibroblasts, lungs were isolated from mice and digested using DNase/
Liberase. Fibroblasts were harvested after 6 days of culture and experiment was
started the subsequent day.
Viruses. We used HSV-1(17+)Lox and HSV-1(17+)Lox-CheVP26 in which
monomeric Cherry has been fused to the N-terminus of the small capsid protein
VP2664, HSV-1F (kindly provided by Prof. Hartmut Hengel, Institute of Virology,
Freiburg, Germany) and HSV-VP16-GFP65 (kindly provided by Dr. Yohei
Yamauchi, University of Bristol, United Kingdom).
Reagents. D-erythro-sphingosine (C18, 860490) and D-Galactosyl-β1-1’-N-Ner-
vonoyl-D-erythro-sphingosine (C24:1, β-D-Galactosyl Ceramide, 110759), were
obtained from Avanti Polar Lipids (Alabaster, AL, USA). Glycoceramidase (E9030-
100MUN), sphingomyelinase (S8633-25UN), Cy3-linked DBCO (777366-1 mg)
and DAPI (D9542) were purchased from Millipore Sigma (Darmstadt, Germany).
Recombinant mouse Asah2 (3558-AH) was purchased from R&D Systems (Min-
neapolis, MN, USA). The sphingosine kinase inhibitor SKI-II (CAS # 312636-16-1;
Cat # 2097) was obtained from Tocris Bioscience (Bristol, United Kingdom) and
tamoxifen (CAS # 10540-29-1, Cat # T5648-5G) and cornoil (CAS # 8001-30-7, Cat
# C8267-500ML) from Millipore Sigma. Clodronate and control liposomes were
purchased from Liposoma (CP-005-005, Amsterdam, Netherlands). Clickable ω-
azido-sphingosine ((2S,3R,E)-2-amino-18-azidooctadec-4-ene-1,3-diol) for click
chemistry42 staining was synthesized in-house by Julian Fink.
Tamoxifen treatment. Tamoxifen was dissolved in corn oil. Eight, six, and four
days before an experiment, Cre- × Asah1fl/fl control animals and Cre+ × Asah1fl/fl
animals were treated with 4 mg tamoxifen (in 100 μL corn oil) intraperitoneally.
Depletion of macrophages. For macrophage-depleted mouse experiments, mice
were treated intravenously with 50 mg/kg clodronate to deplete tissue resident
macrophages. After 3 days, mice were ready to be used in experiments.
Survival experiments. To analyze the effect of macrophage/ sphingosine defi-
ciency on the course of infection, we performed survival experiments. For this
purpose, animals were infected with a dose that was sublethal for WT animals.
Animals were checked daily, killed with corresponding termination criteria, and
counted as dead. Termination criteria were body weight, general condition,
spontaneous behavior and clinical findings.
Bone marrow chimera mice. For bone marrow chimera experiments, 10–12 weeks
old female C57BL/6J mice were irradiated with 9.5 Gy. On the following day, bone
marrow from donor mice was isolated under sterile conditions and i.v. adminis-
tered. On day 10 after irradiation, mice were treated with clodronate liposomes to
deplete tissue resident macrophages. After 50 days of reconstitution mice were
ready to be used in experiments.
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Infection of cells and animals. For in vitro infection, the virus was added to the
cell cultures. After incubation for 1 h, the supernatant was washed away and new
medium was added. The supernatant was collected at various times after infection.
For intravenous infection, 100 µL of the virus was injected into the tail vein. For
intravaginal infection, 20 µL of the virus was pipetted into the vagina of anesthe-
tized mice. The vagina was briefly closed with skin glue to reduce variability of
inoculation time and volume.
Immunofluorescence microscopy. Immunofluorescence was used to detect
viruses in cells and organs. For in vitro experiments, cells were seeded in 24-well
plates, each containing a coverslip. After 24 h, the cells were correspondingly
infected, fixed after incubation, and labeled with antibodies. Organs of infected
animals were snap-frozen, and 8 μm thick sections were recovered on a microscope
slide. The sections were fixed, and virus was visualized with virus-specific anti-
bodies. The following primary antibodies were used: anti-HSV-1 capsid (SY456334,
anti-capsid, 1:100), anti-HSV-1 glycoprotein (hu2c66, anti-glycoprotein gB, 1:200)
or anti-HSV-1 VP5 (NC-141, anti-capsid, 1:500). Alternatively, virus was directly
labeled with a dye (e.g., Cy3; carboxylfluorescein succinimidyl ester [CFSE]) was
used. Zeiss ELYRA PS.1 SIM/PAL-M/STORM/TIRF and LSM710 (ZEISS, Ober-
kochen, Germany), was used to acquire images.
Immunofluorescence microscopy of sphingosine. Immunofluorescence was used
to detect sphingosine in cells. Cells were seeded in 24-well plates, each containing a
coverslip. After 24 h, the cells were correspondingly treated, fixed after incubation,
and labeled with antibodies. As primary antibody monoclonal anti-sphingosine
antibody (clone NHSPH, ALF-274042010, Alfresa Pharma Corporation, Osaka,
Japan, 1:1000) and as secondary antibody Cy3-coupled anti-IgM F(ab)2 fragments
(Jackson ImmunoResearch, Ely, United Kingdom, 1:500) were used. Samples were
examined with a Leica TCS-SP5 confocal microscope equipped with a 100× lens,
and images were analyzed with Leica LCS software version 2.61 (Leica Micro-
systems, Mannheim, Germany). Fluorescence intensity was determined in 100
randomly selected cells/sample (total of 300 cells). We determined the fluorescence
of the cell periphery.
Detection of HSV in cell supernatant/organs by TCID50 assay. For tissue
culture infection dose 50 (TCID50) Vero cells were seeded onto a 96-well plate and
let grow to confluence overnight. To determine the viral titer, cell culture super-
natant or organ suspension was titrated and transferred to the 96-well plate. After
7 days of incubation, the plaque positive wells were counted, and the number of
infectious particles per ml of supernatant or organ was determined.
Detection of HSV in organs by qRT-PCR. For quantitative real-time polymerase
chain reaction (qRT-PCR) DNA was isolated from organs using the innuPREP
Virus DNA Kit (Order #: 845-KS-4600050, Analytik Jena, Jena, Germany). RealStar
HSV PCR Kit 1.0 CE (Order #: 061013, Altona Diagnostics, Hamburg, Germany)
was used to quantify the amount of HSV-1 genomes per organ. A LightCycler 480
Instrument (Roche Life Science, Basel, Switzerland) was used for detection.
Capsid uncoating assay of herpes simplex virus. Cells were incubated with
HSV-1 expressing GFP at the tegument protein VP16 (HSV-1-VP16-GFP65). After
30 min of incubation, cells were fixed and stained for HSV capsid with anti-VP5
(NC-141, 1:500) and DAPI. Images were acquired on Leica SP8 microscope
(Wetzlar, Germany) and analyzed using CellProfiler by segmentation and counting
of single VP16-GFP or VP5 puncta.
Sphingosine-containing liposomes for FACS analysis. Liposomes were prepared
by sonication as previously described67. Phosphatidylcholine (PC), cholesterol
(Ch), sphingomyelin (SM), ceramide (Cer) and D-sphingosine (Sph) were from
Millipore Sigma. The lipid composition of the liposomes was as follows: control-
liposomes (PC: Ch: SM 33.3:33.3:33.3 mol/%), ceramide-rich liposomes (PC: Ch:
SM: Cer 33:33:24:10 mol/%) and sphingosine-rich liposomes (PC: Ch: SM: Sph
33:33:24:10 mol/%).
Isolation of total RNA, reverse transcription and qRT-PCR. Total RNA was
isolated from cells using Trizol. Complementary DNA synthesis was performed
with the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany).
For quantitative real-time polymerase chain reaction (qRT-PCR) either Fast
SYBR Green Master Mix (Applied Biosystems, Darmstadt, Germany) or TaqMan
Fast Universal PCR Master Mix (ThermoFisher Scientific) was used on the 7500
Fast Real-Time PCR System (Applied Biosystems). For analysis, the expression
levels of all target genes were normalized against glyceraldehyde 3-phosphate
dehydrogenase (Gapdh; ΔCt). Relative gene expression values were calculated with
the ΔΔCt method. Following primers were used: Gapdh (Mm99999915_g1,
ThermoFisher Scientific), Gapdh (QT01658692, Qiagen), Asah1
(Mm00480021_m1, ThermoFisher Scientific) IRF7 (Mm00516788_m1,
ThermoFisher Scientific), Isg15 (QT00322749, Qiagen), RnaseL (QT01066086,
Qiagen), Tetherin/Bst2 (QT01066184,Qiagen), IFNα4 (QT01774353, Qiagen),
IFNα5 (QT00327656, Qiagen), IFNβ1 (QT00249662, Qiagen), Mx-1 (QT01064231,
Qiagen), Oas1 (QT01056048, Qiagen) and PKR (QT00162715, Qiagen).
Click chemistry. Clickable ω-azido-sphingosine ((2S,3R,E)-2-amino-18-azi-
dooctadec-4-ene-1,3-diol) was used for click chemistry reaction as described
previously42,68. Briefly, cells were seeded and grown to confluence. ω-azido-
sphingosine was added to cell culture medium (100 μmol/L) for 3 h. Cells were
washed with PBS and then Cy3-linked DBCO (8 μg/ml diluted in PBS) was added
for 7 min at room temperature. Samples were washed 3x with PBS and medium
was added. Cell were further analyzed as described.
For detailed synthesis and analysis of ω-azido-sphingosine see methodical
information “chemical synthesis of ω-azido-sphingosine” in Supplementary
Information and Supplementary Figs. 9–20.
Microarray. Total RNA preparations were checked for RNA integrity with an
Agilent 2100 Bioanalyzer. All samples in this study exhibited high-quality RNA
Integrity Numbers (RIN 9.8-10). Synthesis of cDNA and subsequent fluorescence
labeling of cRNA were performed according to the manufacturer’s protocols (One-
Color Microarray-Based Gene Expression Analysis/Low Input Quick Amp Label-
ing; Agilent Technologies, Waldbronn, Germany). Briefly, 100 ng of total RNA was
converted to cDNA, followed by in vitro transcription and incorporation of Cy3-
CTP into nascent cRNA. After fragmentation, labeled cRNA was hybridized to
AgilentSurePrint G3 Mouse GE 8×60k microarrays for 17 h at 65 °C and scanned
as described in the manufacturer’s protocol. Signal intensities on 20-bit TIFF
images were calculated by Feature Extraction software (FE, Vers. 10.7.1.1; Agilent
Technologies). Data analyses were conducted with GeneSpring GX software (Vers.
10.5; Agilent Technologies). Probe signal intensities were quantile-normalized
across all samples for reduction of inter-array variability. Input data preprocessing
was concluded by baseline transformation to the median of all samples.
To ensure innate immune activation macrophages and fibroblasts were infected
with LCMV and treated with IFN-α4. To analyze the microarray data a gene set
enrichment analysis with GSEA (Broad Institute, v3.069) using the Gene Ontology
Cellular Components (CC) gene set database (c5.cc.v6.270, accessed on 15.07.19)
was performed using default settings. Results were further subjected to network
analysis using the Enrichment Map plugin v3.2.0 in Cytoscape v3.7.1 with the
following settings: FDR q-value cutoff 0.05, p-value cutoff 1, Metric: Jaccard
+Overlap Combined (50/50) with cutoff 0.375. Clusters were identified by the
AutoAnnotate plugin v1.3 and labeled manually for visualization. For visualization
gene sets upregulated in LCMV-infected and interferon-treated macrophages or
fibroblasts were sorted to the left or right side of the diagram respectively. Several
membrane modulating proteins from the families of sphingolipids (including
gangliosides), cholesterol and phosphatidylcholine were considered for simplified
comparison of macrophages and fibroblasts (see Supplementary Table 2).
Virus binding to liposomes. Liposomes were incubated with fluorescently labeled
virus. Samples were diluted and further analyzed in flow cytometry (LSR Fortessa).
Liposomes were detected by size and granularity. Frequency of liposomes, which
bound the virus was determined by fluorescence according to the gating shown in
Fig. 5f. Data was analyzed using the software FlowJo (FlowJo LLC).
FACS Sorting. Bone marrow was isolated from tibia and femur of mice and
erythrocytes were lysed. To sort pre-progenitor cells staining for linage markers
anti-CD3e (Cat # 45-0031-80, eBioscience, 1:50), anti-GR1 (Cat # 108428, Bio-
Legend, 1:400), anti-Mac-1 (Cat # 101228, BioLegend, 1:400), anti-CD4 (Cat #
101228, BioLegend, 1:200), anti-CD8a (Cat # 100734, BioLegend, 1:100), anti-
TCRb (Cat # 109228, BioLegend, 1:100), anti-NK1.1 (Cat # 45-5941-82,
eBioscience, 1:100), anti-B220 (Cat # 103236, BioLegend, 1:100) and anti-CD19
(Cat # 115534, BioLegend, 1:200) was performed. Additionally anti-CD16/32 (Cat
# 101305, BioLegend, 1:200), anti-CD41 (Cat # 133906, BioLegend, 1:100), anti-
Sca-1 (Cat # 108114, BioLegend, 1:200), anti-c-kit (Cat # 47-1171-82, Invitrogen,
1:50), anti-CD105 (Cat # 120412, BioLegend, 1:50) and anti-CD150 (Cat # 115910,
BioLegend, 1:400) were stained to further classify cells. To sort immature granu-
locytes, mature granulocytes and monocytes anti-Ly6G/Ly6C (Cat # 17-5931-82,
Invitrogen, 1:100), anti-CD11b (Cat # 25-0112-82, eBioscience, 1:100) and anti-
CD115 (Cat # 11-1031-85, eBioscience, 1:100) were used. Gating strategy was
performed as shown in Supplementary Fig 5.
Western blot for aCDase protein expression. Frozen mouse spleen or cultured
primary mouse cells were lysed in radioimmunoprecipitation buffer containing 1x
HALT Protease Inhibitor Cocktail and 50 mM EDTA (Thermo Fisher, Cat. no.
78430) using 100 µl lysis buffer per 10 mg organ or 30 µl lysis buffer per 106 cells
respectively. Spleens were homogenized using a homogenizer (Qiagen Tissue Lyser
II, Cat. no. 85300) for 2 min at 20 Hz. Lysates were then centrifuged for 20 min at
20,000 x g at 4 °C, keeping the supernatants. Protein concentration was measured
using detergent compatible (DC) Protein Assay (Bio-Rad, Cat. no. 5000112),
standardized to 4 µg/µl and prepared for SDS-PAGE by addition of 4x Laemmli
sample buffer (Bio-Rad, Cat. no. 1610747), incubation at 95 °C for 5 min followed
by cool-down on ice. 30 µg per organ or 10 µg per cell lysate was loaded per
lane into a precast TGX AnyKD Stain-free gel (Bio-Rad, Cat. no. 4568126), using
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Bio-Rad AllBlue protein standard (Cat. no. 1610373) and ran for 45 min at 140 V
in Tris/glycine/SDS running buffer (Bio-Rad, Cat. no. 1610732). Transfer was
performed using the Trans-Blot Turbo system (Bio-Rad, Cat. no. 1704150) with
Mini PVDF Transfer Packs (Bio-Rad, Cat. no. 1704156). Membranes were blocked
in Pierce StartingBlock (TBS) Blocking Buffer (Thermo Fisher, Cat. no. 37542) for
2 h and primary antibody was incubated shaking at 4 °C for 2 days: 1:500 for anti-
aCDase rabbit polyclonal (Proteintech, Cat. no. 11274-1-AP) for spleens, or 1:500
anti-aCDase rabbit polyclonal (ProSci, Cat. no. 4741) for cell lysates, and 1:1000
for anti-GAPDH mouse (Meridian Life Science, Cat. no. H86504M) diluted in
blocking buffer. Membranes were washed three times with Tris-buffered saline-0.1
% Tween 20 (TBS-T) and incubated with secondary antibody at 1:5000 (from GE
Life Sciences, anti-Rabbit IgG, HRP-linked, Cat. no. NA934 or anti-mouse IgG,
HRP linked, Cat no. NA931) diluted in 25 % blocking buffer in TBS-T shaking at
room temperature for 2 h. After washing twice in TBS-T and twice in TBS
membranes were incubated with Pierce ECL (Thermo Fisher, Cat. no. 32106) for 5
min and imaged on a Bio-Rad ChemiDoc MP (Cat. no. 1708280) with ImageLab
version 6.0.1 (Bio-Rad).
Histology. Histological analysis of snap-frozen liver and spleen tissues or cell
cultures was performed with monoclonal fluorescence labeled antibodies against
HSV-1-capsid (SY4563, 1:100) anti-HSV-1 (hu2c66, anti-gB, 1:200), anti-F4/80
(12-4801-82, eBioscience, San Diego, CA, USA, 1:100), anti-Asah1 (4741, ProSci,
San Diego, CA, USA, 1:200), anti-CD9 (124809, Biolegend, San Diego, CA, USA,
1:100) and anti-sphingosine (clone NHSPH, ALF-274042010, Alfresa Pharma
Corporation, Osaka, Japan, 1:1000). Nuclei were stained using Hoechst 33342 (Cat
# B2261-100MG, Sigma, 1:5000). Zeiss ELYRA PS.1 SIM/PAL-M/STORM/TIRF
and LSM710, Leica SP8 gSTED and FLIM, Leica TCS-SP5, or Keyence BZ-9000
(Keyence, Osaka, Japan) were used to acquire images. Quantification of histology
was done using standard procedures in Fiji software version 1.52e (Image J, NIH,
Bethesda, MD, USA) or Cell Profiler71. In Fiji we used the raw images, applied a
mean filter of two/ten to exclude noise. We took the total signal area and the
intensity per area after an empirically fixed threshold for further evaluation.
Mass spectrometry analysis. 106 cells were subjected to lipid extraction with 1.5mL
methanol/chloroform (2:1, v:v)72. The extraction solvent contained d7-sphingosine
(d7-Sph), C17-ceramide, and C16-d31-sphingomyelin (all from Avanti Polar Lipids)
as internal standards. Sample analysis was carried out by liquid chromatography
tandem-mass spectrometry (LC-MS/MS) using either a TQ 6490 mass spectrometer
(for Sph) or a QTOF 6530 mass spectrometer (for ceramides and sphingomyelins)
(both from Agilent Technologies, Waldbronn, Germany) operating in the positive
electrospray ionization mode (ESI+). The following selected reaction monitoring
(SRM) transitions were used for quantification: m/z 300.3 → 282.3 for Sph and m/z
307.3 → 289.3 for d7-Sph. The precursor ions of ceramide or sphingomyelin species
(differing in the lengths of their fatty acid chains) were cleaved into the fragment ions
m/z 264.270 (for ceramide) or m/z 184.074 (for sphingomyelin), respectively73.
Quantification was performed with Mass Hunter Software (Agilent Technologies).
Electron microscopy. The samples were fixed with glutaraldehyde (2.5% in
100 mM phosphate buffer). Cells were then contrasted with 1% osmium tetroxide,
1% thiocarbohydrazide, 1.5% potassium ferrocyanide, and 1% uranyl acetate in
water and were then dehydrated in an ascending ethanol row (50%, 70%, 96%, and
3 × 100%, 10 min each) and stepwise (EPON/EtOH 1:1 and 2:1 each for 2 h, EPON
overnight) flat-embedded in EPON resin. Subsequently, EPON-embedded samples
were polymerized for 24 h at 60 °C. After removal of the glass slide with 40%
aqueous hydrofluoric acid, the EPON disk, containing the cells of interest, was
removed from the dish, mounted on EPON resin blocks, and processed for
ultramicrotomy. Serial sections were cut with a Leica EM UC7 ultramicrotome
(Leica Microsystems) set to a thickness of 55 nm. A final post staining of the
ultrathin sections was perfomed for 6 min on a drop of 1% uranylacetate followed
by 1% lead citrate for 3 min in aqueous solution.
Transmission electron microscopy (TEM) was conducted on a Jeol 1400FPlus
(Tokyo, Japan) instrument at 120 kV with magnifications as indicated. Digital
images were acquired with a 4096×4096-pixel complementary metal-oxide
semiconductor (CMOS) camera (TemCam-F416, TVIPS; Gauting, Germany).
Postprocessing of the resulting 16-bit TIFF image files was performed with Fiji
software version 1.52e (Image J). Pixel noise was averaged by a gaussian blur
algorithm. A background resulting from inhomogeneous illumination was removed
by implementing the “rolling ball” procedure, and the contrast was adjusted with
histogram normalization.
Statistical analysis. If not mentioned otherwise, data are expressed as arithmetic
mean ± SEM and n represents the number of mice. Student’s t-test (two-tailed, if
not indicated otherwise) in case of normal distribution or in case of multiple
comparisons ANOVA, were used to detect statistically significant differences.
p-Values of 0.05 or less were considered statistically significant. Statistical analyses
and graphical presentations were computed with Graph Pad Prism software
(Graph Pad, La Jolla, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
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